BOOST Pharma outlines placebo-controlled trial of up to 80 patients for brittle bone cell therapy BT-101 at Meeting on the Mesa
CEO Hans Schambye told Cell & Gene Meeting on the Mesa that BOOST Pharma expects to be able to start a placebo-controlled trial of BT-101, its investigational stem cell therapy for osteogenesis imperfecta, in the middle of next year.